<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976544</url>
  </required_header>
  <id_info>
    <org_study_id>HRT_NC-FET</org_study_id>
    <secondary_id>2018-003156-20</secondary_id>
    <nct_id>NCT03976544</nct_id>
  </id_info>
  <brief_title>Natural Cycle Versus Hormone Replacement Therapy Cycle for a Frozen-thawed Embryo Transfer in PGT Patients</brief_title>
  <official_title>Natural Cycle Versus Hormone Replacement Therapy Cycle for a Frozen-thawed Embryo Transfer in PGT Patients: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CRG UZ Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CRG UZ Brussel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is to compare miscarriage rates (before 8 weeks) between a true
      natural cycle (awaiting spontaneous LH surge) and a hormone replacement therapy cycle prior
      to blastocyst transfer in preimplantation genetic testing (PGT) patients, with biopsy on day
      5 of embryonic development. The advantage of performing the study in PGT patients is the
      exclusion of aneuploidy as a cause of miscarriage.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized to either natural cycle frozen-thawed embryo transfer (group A), or hormonal replacement therapy cycle frozen-thawed embryo transfer (group B).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Miscarriage rate before 8 weeks of gestation</measure>
    <time_frame>8 weeks</time_frame>
    <description>a spontaneous loss of a clinical pregnancy before 8 weeks of gestational age, in which the embryo(s) is/are nonviable and is/are (not) spontaneously absorbed or expelled from the uterus per initiated embryo transfer cycle and per positive hCG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate after 8 weeks of gestation</measure>
    <time_frame>22 weeks</time_frame>
    <description>a spontaneous loss of a clinical pregnancy after 8 weeks but before 22 completed weeks of gestational age, in which the embryo(s) or fetus(es) is/are nonviable and is/are not spontaneously absorbed or expelled from the uterus per initiated embryo transfer cycle and per positive hCG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>7 weeks</time_frame>
    <description>a pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy per initiated embryo transfer cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>20 weeks</time_frame>
    <description>the number of pregnancies after 20 weeks of gestation per initiated embryo transfer cycle</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">522</enrollment>
  <condition>Miscarriage</condition>
  <condition>Frozen Embryo Transfer</condition>
  <condition>Natural Cycle</condition>
  <condition>Hormone Replacement Therapy Cycle</condition>
  <condition>Preimplantation Genetic Screening</condition>
  <condition>Euploid Embryos</condition>
  <arm_group>
    <arm_group_label>Natural cycle</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients are asked to perform a blood sample, with evaluation of serum estradiol (E2), progesterone (P), luteinizing hormone (LH) and follicle stimulating hormone (FSH), on the first or second day of the menstrual cycle. If these serum hormonal values are considered basal for the beginning of the follicular phase, patients are asked to come back on day 10 to 12 of the cycle for blood sample and transvaginal ultrasound scan in order to assess follicular growth.
The timing of ovulation is determined based on a combination of ultrasonography features (the presence of a dominant follicle and adequate endometrium) and endocrine hormonal values in serum blood samples. Ovulation is generally defined as an, at least, 180% increase of LH compared to the mean level in the previous 24h.
Frozen-warmed blastocyst transfer will take place six days following the spontaneous LH surge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hormone replacement therapy cycle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are asked to perform a blood sample, with evaluation of serum estradiol (E2), progesterone (P), luteinizing hormone (LH) and follicle stimulating hormone (FSH) on the first or second day of the menstrual cycle. If these values are considered basal for the beginning of the follicular phase, estrogen supplementation (Estradiol valerate, Progynova® 3x2mg/day) is started to induce proliferation of the endometrium. Blood sample and transvaginal ultrasound are thereafter performed ten to fourteen days later. If the endometrium is considered adequate (generally considered if triple line and above 6,5 mm thickness), embryo transfer is scheduled on the sixth day of progesterone (vaginal micronized progesterone, Utrogestan® 2x200mg twice a day) supplementation.
In case of escape spontaneous ovulation embryo transfer will be performed considering the presumable time of ovulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol Valerate</intervention_name>
    <description>Estradiol valerate will be started in the beginning of the menstrual cycle in order to induce proliferation of the endometrium.</description>
    <arm_group_label>Hormone replacement therapy cycle</arm_group_label>
    <other_name>Progynova</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micronized progesterone</intervention_name>
    <description>If the endometrium is considered adequately proliferated, micronized progesterone is administered and frozen-thawed blastocyst transfer will take place on the 6th day of supplementation.</description>
    <arm_group_label>Hormone replacement therapy cycle</arm_group_label>
    <other_name>Utrogestan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI under 35 kg/m2

          -  Regular menstrual cycle pattern (i.e. 24-35 days cycle)

          -  First, second and third ICSI-PGT cycle

          -  First frozen embryo transfer cycle following a fresh ICSI-PGT attempt

          -  PGT with trophectoderm biopsy on day 5 of embryonic development

          -  Signed informed consent

        Exclusion Criteria:

          -  Oligo-amenorrhea

          -  BMI above 35

          -  Contraindications for the use of hormonal replacement therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre for Reproductive Medicine UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsie Nulens</last_name>
      <phone>+32 2 477 66 48</phone>
      <email>Studieverpleegkundigen_CRG@UZBrussel.be</email>
    </contact>
    <investigator>
      <last_name>Christophe Blockeel, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Roelens, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CRG UZ Brussel</investigator_affiliation>
    <investigator_full_name>Caroline Roelens</investigator_full_name>
    <investigator_title>Clinical fellow</investigator_title>
  </responsible_party>
  <keyword>frozen-thawed embryo transfer</keyword>
  <keyword>FET</keyword>
  <keyword>natural cycle</keyword>
  <keyword>hormone replacement therapy cycle</keyword>
  <keyword>miscarriage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03976544/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

